Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement

Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Senel, M., Abu‐Rumeileh, S., Michel, D., Garibashvili, T., Althaus, K., Kassubek, J., Otto, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436567/
https://www.ncbi.nlm.nih.gov/pubmed/32781484
http://dx.doi.org/10.1111/ene.14473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436567/
https://www.ncbi.nlm.nih.gov/pubmed/32781484
http://dx.doi.org/10.1111/ene.14473

Ejemplares similares